Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription 01.04.2024 1 AJR Am J Roentgenol 1 Am J Clin Oncol 1 Am J Pathol 1 Ann Surg 2 Ann Surg Oncol 5 Anticancer Res 4 BMC Cancer 1 Br J Cancer 2 Breast Cancer Res 12 Breast Cancer Res Treat 1 Cancer 12 Clin Breast Cancer 1 Clin Exp Metastasis 1 Eur J Surg Oncol 3 Int J Cancer 1 J Clin Oncol 1 J Nucl Med 1 J Surg Oncol 2 Lancet Oncol 1 Nat Rev Clin Oncol 1 NPJ Breast Cancer 5 PLoS One 3 Radiology 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. GASTOUNIOTI A, Kontos D
   Artificial Intelligence in Breast Imaging Daily Clinical Practice: Point-Reshaping Breast Cancer Screening.
   AJR Am J Roentgenol. 2024 Mar 27. doi: 10.2214/AJR.24.31174.
   PubMed        
   
   

   
   Am J Clin Oncol

2. NICHOLSON G, Carlson KB, Hernandez RK, Schenfeld J, et al
   Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
   Am J Clin Oncol. 2024;47:177-184.
   PubMed         Abstract available
   
   

   
   Am J Pathol

3. LINSCOTT M, Ren JR, Gestl S, Gunther EJ, et al
   Different oncogenes and reproductive histories shape the progression of distinct premalignant clones in multistage mouse breast cancer models.
   Am J Pathol. 2024 Mar 25:S0002-9440(24)00112.
   PubMed         Abstract available
   
   

   
   Ann Surg

4. GOEL N, Hernandez AE, Antoni MH, Kesmodel S, et al
   ZIP Code to Genomic Code: Neighborhood Disadvantage, Aggressive Breast Cancer Biology, and Breast Cancer Outcomes.
   Ann Surg. 2024 Mar 28. doi: 10.1097/SLA.0000000000006283.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

5. SCODARI BT, Schaefer AP, Kapadia NS, Brooks GA, et al
   The Association Between Oncology Outreach and Timely Treatment for Rural Patients with Breast Cancer: A Claims-Based Approach.
   Ann Surg Oncol. 2024 Mar 27. doi: 10.1245/s10434-024-15195.
   PubMed         Abstract available
   
   
6. NIJVELDT JJ, Rajan KK, Boersma K, Noorda EM, et al
   Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis.
   Ann Surg Oncol. 2024 Mar 24. doi: 10.1245/s10434-024-15182.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. SATO M, Han Q, Mori R, Mizuta K, et al
   Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methion
   Anticancer Res. 2024;44:1499-1504.
   PubMed         Abstract available
   
   
8. CIMPEAN AM, Comsa S, Sturza A, Barb AC, et al
   Validation of Human Bone Marrow-derived Mesenchymal Stem Cells and MCF-7 Breast Cancer Cells Co-culture Using a 3D Perfused Biomimetic Microfluidic Platform.
   Anticancer Res. 2024;44:1441-1453.
   PubMed         Abstract available
   
   
9. KITSUYA N, Matsuoka M, Onodera T, Yokota I, et al
   Surgical Resection of Primary Tumor for Bone Metastatic Breast Cancer Patients at Initial Presentation.
   Anticancer Res. 2024;44:1591-1601.
   PubMed         Abstract available
   
   
10. RADES D, Kristiansen C, Timke C, Duma MN, et al
    Clinically Significant Dermatitis During Adjuvant Radiotherapy for Invasive Breast Cancer.
    Anticancer Res. 2024;44:1525-1531.
    PubMed         Abstract available
    
    
11. ARDAVANIS-LOUKERIS G, Kokkali S, Perdikari K, Karatrasoglou E, et al
    A Real-world Study of Everolimus Plus Aromatase Inhibitor in Hormone Receptor-positive, HER2-negative Advanced Breast Cancer.
    Anticancer Res. 2024;44:1559-1565.
    PubMed         Abstract available
    
    

    
    BMC Cancer

12. HUANG W, Wang C, Shen Y, Chen Q, et al
    Correction: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
    BMC Cancer. 2024;24:378.
    PubMed        
    
    
13. CHEHELGERDI M, Khorramian-Ghahfarokhi M, Dehkordi FB, Chehelgerdi M, et al
    Comment on "A novel super-enhancer-related gene signature predicts prognosis and immune microenvironment for breast cancer".
    BMC Cancer. 2024;24:377.
    PubMed         Abstract available
    
    
14. ESMAT E, Haidary AM, Saadaat R, Rizvi SN, et al
    Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan.
    BMC Cancer. 2024;24:388.
    PubMed         Abstract available
    
    
15. ZAHEDI H, Alizadeh-Dibazari Z, Mirghafourvand M, Sahebihagh MH, et al
    The effectiveness of couple-based interventions on the marital outcomes of women with genital and breast cancer and their partners: a systematic review and meta-analysis.
    BMC Cancer. 2024;24:391.
    PubMed         Abstract available
    
    

    
    Br J Cancer

16. LIU X, Cheng X, Xie F, Li K, et al
    Persistence of peripheral CD8 + CD28- T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer.
    Br J Cancer. 2024 Mar 22. doi: 10.1038/s41416-024-02610.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

17. QIAN J, Ma Y, Tahaney WM, Moyer CL, et al
    Correction: The novel phosphatase NUDT5 is a critical regulator of triple-negative breast cancer growth.
    Breast Cancer Res. 2024;26:53.
    PubMed        
    
    
18. MULLOOLY M, Fan S, Pfeiffer RM, Bowles EA, et al
    Temporal changes in mammographic breast density and breast cancer risk among women with benign breast disease.
    Breast Cancer Res. 2024;26:52.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

19. HARDY-ABELOOS C, Xiao J, Oh C, Barbee D, et al
    Effectiveness and toxicity of five-fraction prone accelerated partial breast irradiation.
    Breast Cancer Res Treat. 2024;204:485-495.
    PubMed         Abstract available
    
    
20. VAN HEMERT A, van Loevezijn AA, Bosman A, Vlahu CA, et al
    Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome.
    Breast Cancer Res Treat. 2024;204:497-507.
    PubMed         Abstract available
    
    
21. WANG H, Yee D, Potter D, Jewett P, et al
    Impact of body mass index on pathological response after neoadjuvant chemotherapy: results from the I-SPY 2 trial.
    Breast Cancer Res Treat. 2024;204:589-597.
    PubMed         Abstract available
    
    
22. FLETCHER KA, Alkurashi MH, Lindsay AJ
    Endosomal recycling inhibitors downregulate estrogen receptor-alpha and synergise with endocrine therapies.
    Breast Cancer Res Treat. 2024;204:631-642.
    PubMed         Abstract available
    
    
23. WALSH EA, Post K, Massad K, Horick N, et al
    Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.
    Breast Cancer Res Treat. 2024;204:547-559.
    PubMed         Abstract available
    
    
24. COLLIN LJ, Jones J, Nash R, Switchenko JM, et al
    Racial disparities in initiation of chemotherapy among breast cancer patients with discretionary treatment indication in the state of Georgia.
    Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07279.
    PubMed         Abstract available
    
    
25. DOUBBLESTEIN D, Koehler L, Anderson E, Scheiman N, et al
    Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains.
    Breast Cancer Res Treat. 2024 Mar 22. doi: 10.1007/s10549-024-07298.
    PubMed         Abstract available
    
    
26. GODINEZ PAREDES JM, Rodriguez I, Ren M, Orozco A, et al
    Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies.
    Breast Cancer Res Treat. 2024 Mar 23. doi: 10.1007/s10549-024-07300.
    PubMed         Abstract available
    
    
27. KAPLAN HG, Dowdell AK, Berry AB, Shimol RB, et al
    Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
    Breast Cancer Res Treat. 2024 Mar 24. doi: 10.1007/s10549-024-07270.
    PubMed         Abstract available
    
    
28. TENG YT, Wang YA, Dong YH, Liu JJ, et al
    Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07280.
    PubMed         Abstract available
    
    
29. JUNG JJ, Cheun JH, Kim HK, Lee HB, et al
    Comparison of long-term oncologic outcomes of central lumpectomy and conventional breast-conserving surgery for invasive breast cancer: propensity score matching analysis.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07297.
    PubMed         Abstract available
    
    
30. GULIYEV M, Sen GA, Gulturk I, Majidova N, et al
    The effects of low HER2 expression on survival in patients with metastatic breast cancer treated with CDK 4/6 inhibitors: a multicenter retrospective study.
    Breast Cancer Res Treat. 2024 Mar 25. doi: 10.1007/s10549-024-07291.
    PubMed         Abstract available
    
    

    
    Cancer

31. WANG X, O'Regan RM
    Breast cancer therapy in China: Introducing the Special Collection.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35288.
    PubMed        
    
    

    
    Clin Breast Cancer

32. DAVEY MG, Tormey S
    Implications of Highly Penetrant Genetic Variants on Breast Surgery.
    Clin Breast Cancer. 2024;24:180-183.
    PubMed         Abstract available
    
    
33. NAG S, Berlin L, Hunter K, Bonawitz SC, et al
    Effects of Neoadjuvant Chemotherapy on Autologous and Implant-Based Breast Reconstruction: A Systematic Review and Meta-Analysis of the Literature.
    Clin Breast Cancer. 2024;24:184-190.
    PubMed         Abstract available
    
    
34. CHI Y, Hirachan S, Zhou Y, Bhandari A, et al
    Exploring the Oncogenic Potential of TIMM8A: A Crucial Factor in Breast Cancer Tumorigenesis.
    Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00049.
    PubMed         Abstract available
    
    
35. GRZYWACZ VP, Lehrberg AV, Quinn TJ, Zureick AH, et al
    Breast Conserving Therapy for Patients With Prior Cosmetic Implant-Based Breast Augmentation: Outcomes and Comparison Against a Matched Cohort.
    Clin Breast Cancer. 2024;24:227-236.
    PubMed         Abstract available
    
    
36. DURAN C, Ward RC, Dibble EH
    (18)F-FES PET/CT for Post-Cryoablation Evaluation of Breast Cancer.
    Clin Breast Cancer. 2024 Feb 28:S1526-8209(24)00043.
    PubMed        
    
    
37. LI G, Huang Z, Luo H, Tian H, et al
    Photoacoustic Imaging Radiomics to Identify Breast Cancer in BI-RADS 4 or 5 Lesions.
    Clin Breast Cancer. 2024 Feb 29:S1526-8209(24)00055.
    PubMed         Abstract available
    
    
38. STAFFORD L, Sinclair M, Butow P, Hughes J, et al
    Quality of Life Outcomes Associated With Optimization of Treatment by Omitting Radiotherapy in Early Breast Cancer.
    Clin Breast Cancer. 2024 Mar 6:S1526-8209(24)00062.
    PubMed         Abstract available
    
    
39. MA S, Liu Y, Gao P, Ma R, et al
    Independent Validation of the BRENDA-Score Breast Cancer Prognosis Prediction Tool In Chinese Patients.
    Clin Breast Cancer. 2024 Feb 28:S1526-8209(24)00058.
    PubMed         Abstract available
    
    
40. SONDERGAARD SR, Stie M, Bechmann T, Offersen BV, et al
    Through Clinicians Eyes: Use of an In-consultation Patient Decision Aid in Radiation Treatment for Early Breast Cancer. A Qualitative Study.
    Clin Breast Cancer. 2024 Feb 21:S1526-8209(24)00045.
    PubMed         Abstract available
    
    
41. DAI L, Yan W, Ren X, Liu D, et al
    Construction and Validation of a Nomogram Predicting the Overall Survival Benefit of Unilateral Breast Cancer Patients Undergoing Contralateral Prophylactic Mastectomy.
    Clin Breast Cancer. 2024 Feb 7:S1526-8209(24)00039.
    PubMed         Abstract available
    
    
42. XU D, Wang K, Lin C, Li D, et al
    Can We Do Breast-Conserving Surgery Without Intraoperative Frozen Section of Margin?
    Clin Breast Cancer. 2024;24:191-198.
    PubMed         Abstract available
    
    
43. SFARAD HK, Allweis TM
    Postoperative Complications Following Lumpectomy With Intraoperative X-Ray Radiation Therapy: A Retrospective Comparative Study.
    Clin Breast Cancer. 2024;24:237-242.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

44. LEDUC S, Nguyen HL, Richard F, Zels G, et al
    Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.
    Clin Exp Metastasis. 2024 Mar 29. doi: 10.1007/s10585-024-10279.
    PubMed         Abstract available
    
    

    
    Eur J Surg Oncol

45. TASOULIS MK, Muktar S, Smith I, Roche N, et al
    Omission of breast surgery in selected breast cancer patients with excellent response to neoadjuvant systemic therapy.
    Eur J Surg Oncol. 2024;50:108277.
    PubMed         Abstract available
    
    

    
    Int J Cancer

46. WANG T, Chai B, Chen WY, Holmes MD, et al
    Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
    PubMed         Abstract available
    
    
47. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
    Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
    Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
    PubMed         Abstract available
    
    
48. WU H, Wang W, Zhang Y, Chen Y, et al
    Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
    Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

49. MARTIN M, Lim E, Chavez-MacGregor M, Bardia A, et al
    Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
    J Clin Oncol. 2024 Mar 27:JCO2301500. doi: 10.1200/JCO.23.01500.
    PubMed         Abstract available
    
    

    
    J Nucl Med

50. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    PubMed         Abstract available
    
    

    
    J Surg Oncol

51. VALENTE S, Roesch E
    Breast cancer survivorship.
    J Surg Oncol. 2024 Mar 27. doi: 10.1002/jso.27627.
    PubMed         Abstract available
    
    

    
    Lancet Oncol

52. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Lancet Oncol. 2024;25:474-487.
    PubMed         Abstract available
    
    
53. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
    Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024;25:e139-e151.
    PubMed         Abstract available
    
    

    
    Nat Rev Clin Oncol

54. SIDAWAY P
    KN046 shows tolerability and activity in TNBC.
    Nat Rev Clin Oncol. 2024;21:251.
    PubMed        
    
    

    
    NPJ Breast Cancer

55. KULKARNI AA, Jain A, Jewett PI, Desai N, et al
    Association of antibiotic exposure with residual cancer burden in HER2-negative early stage breast cancer.
    NPJ Breast Cancer. 2024;10:24.
    PubMed         Abstract available
    
    

    
    PLoS One

56. NIU X, Wang J, Liu J, Yu Q, et al
    17beta-Estradiol promotes metastasis in triple-negative breast cancer through the Calpain/YAP/beta-catenin signaling axis.
    PLoS One. 2024;19:e0298184.
    PubMed         Abstract available
    
    
57. EBRAHIMPOUR-KOUJAN S, Benisi-Kohansal S, Azadbakht L, Fallah M, et al
    Adherence to HEI-2010 and odds of breast cancer according to the menopause status: Evidence from Middle Eastern Country.
    PLoS One. 2024;19:e0300986.
    PubMed         Abstract available
    
    
58. DEMEKE T, Hailemariam D, Santos P, Seife E, et al
    Willingness and ability to pay for breast cancer treatment among patients from Addis Ababa, Ethiopia: A cross-sectional study.
    PLoS One. 2024;19:e0300631.
    PubMed         Abstract available
    
    
59. RAGHURAM GV, Pal K, Sriram G, Khan A, et al
    Correction: Therapeutic interventions on human breast cancer xenografts promote systemic dissemination of oncogenes.
    PLoS One. 2024;19:e0301650.
    PubMed         Abstract available
    
    
60. 
    Retraction: Long Non-Coding RNA HOTAIR Regulates the Proliferation, Self-Renewal Capacity, Tumor Formation and Migration of the Cancer Stem-Like Cell (CSC) Subpopulation Enriched from Breast Cancer Cells.
    PLoS One. 2024;19:e0300804.
    PubMed        
    
    

    
    Radiology

61. KUHL CK
    Abbreviated Breast MRI: State of the Art.
    Radiology. 2024;310:e221822.
    PubMed         Abstract available
    
    
62. ZHOU LQ, Wu XL, Huang SY, Wu GG, et al
    Erratum for: Lymph Node Metastasis Prediction from Primary Breast Cancer US Images Using Deep Learning.
    Radiology. 2024;310:e249009.
    PubMed        
    
    
63. CHEN Y, Taib AG, Darker IT, James JJ, et al
    Erratum for: Performance of a Breast Cancer Detection AI Algorithm Using the Personal Performance in Mammographic Screening Scheme.
    Radiology. 2024;310:e249007.
    PubMed        
    
    

    
    Radiother Oncol

64. FRANCESCHINI D, Franzese C, Comito T, Ilieva MB, et al
    Definitive results of a prospective non-randomized phase 2 study on stereotactic body radiation therapy (sbrt) for medically inoperable lung and liver oligometastases from breast cancer.
    Radiother Oncol. 2024;195:110240.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.